Zero Approved Drugs, $28M Profit: A Biotech Run by an Ex-Analyst

Most Chinese biotechs that list under the STAR Market's "Standard 5" rules (no profitability requirement, but at least one drug in Phase II trials) are money-losing — that's the whole point of the rule. Xinnuowei Pharma (信诺维, 688050.SH) broke the pattern: RMB 935M in 2025 revenue, RMB 203M (~$28M) in net profit — with zero drugs approved for sale.

Its founder, Qiang Jing, wasn't a scientist or pharma executive before starting the company in 2017. He was CICC's (China International Capital Corporation) chief pharmaceutical industry analyst — the person whose job was to evaluate other companies' drug pipelines, not build his own.

Xinnuowei's pipeline follows a "1+3+N" structure: one New Drug Application already accepted for review, three assets in Phase III trials, and a broader early-stage portfolio behind them. But the real story is how it made money before any of those drugs reached the market: through licensing deals (BD, or "business development" deals in Chinese biotech parlance) with major pharma companies including Japan's Astellas and China's Zhengda Antibody. Cumulative potential deal value across these licensing agreements: over $2 billion, with a single recent deal carrying a $130M upfront payment and $1.4B in potential milestone payments.

That's the trick: instead of racing to build a sales force and market a drug directly, Xinnuowei licenses out development and commercialization rights to bigger players, collecting upfront cash and milestone payments along the way. It's a well-worn model in Western biotech but rare in China at this scale. Qiang's analyst background is arguably the whole edge here — he spent years studying exactly what global pharma companies look for in a licensing target, which drug targets and indications they'll pay for, and how such deals get negotiated and priced.

The company is raising RMB 2.94B in its August 2026 IPO (15% of post-issue shares) to fund further R&D. The obvious risk: none of this profit comes from actual drug sales. If the pending NDA doesn't get approved, or Phase III data disappoints, milestone payments can evaporate or trigger contract-termination clauses — and the entire profitable-biotech story depends on Qiang's dealmaking continuing to work as well as it has so far.

This is a simulated-portfolio research note based on public disclosures, not investment advice. Markets carry risk.